Search Result

Results for "

PARP-IN-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PARP (61) Akt (1) Apoptosis (12) Autophagy (2) Bcl-2 Family (1) Caspase (4) DNA/RNA Synthesis (1) Dynamin (1) Endogenous Metabolite (3) Epigenetic Reader Domain (1) MDM-2/p53 (1) Microtubule/Tubulin (3) Mitophagy (1) P-glycoprotein (1) p38 MAPK (1) PI3K (1) Poly(ADP-ribose) Glycohydrolase (PARG) (2) PPAR (1) PROTACs (1) Proteasome (1) Topoisomerase (1) VEGFR (1)
By Research Areas:	Cancer (52) Cardiovascular Disease (2) Inflammation/Immunology (5) Metabolic Disease (2) Neurological Disease (7)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: PARP AIM2 NEKs

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12022

3-Aminobenzamide 5+ Cited Publications PARP-IN-1	PARP	Cancer
3-Aminobenzamide (PARP-IN-1) is a potent inhibitor of PARP* with IC₅₀ of* appr 50 nM in CHO cells, and acts as a mediator of oxidant-induced myocyte dysfunction during reperfusion.

HY-161302

Polθ/PARP-IN-1	Apoptosis DNA/RNA Synthesis PARP	Cancer
Polθ/PARP-IN-1 (compound 25d) is a potent dual DNA polymerase theta (Polθ) and *PARP* inhibitor with IC₅₀ values of 45.6, 5.4 nM, respectively. Polθ/PARP-IN-1 shows antiproliferative activity. Polθ/PARP-IN-1 induces apoptosis and cell cycle arrest at G2/M phase, causes DNA damage. Polθ/PARP-IN-1 shows anti-tumor activity ^[1].

HY-155965

VEGFR/PARP-IN-1	VEGFR PARP Apoptosis	Cancer
VEGFR/PARP-IN-1 (Compound 14b) is a *VEGFR/PARP* dual inhibitor (IC₅₀s: 191 nM and 60.9 nM respectively). VEGFR/PARP-IN-1 inhibits DNA damage repair, induces cell apoptosis, and arrests cell in the G2/M phase. VEGFR/PARP-IN-1 has good antiproliferative efficacy against BRCA wild-type breast cancer cells (IC₅₀: 4.1 and 3.5 μM for MDA-MB-231 and MCF-7 cells). VEGFR/PARP-IN-1 is an antitumor and anti-metastasis agent ^[1].

HY-157165

Tubulin/PARP-IN-1	Microtubule/Tubulin PARP	Cancer
Tubulin/PARP-IN-1 (compound 14) is a dual PARP-tubulin inhibitor with activity against endometrial cancer. *Tubulin/PARP*-IN-1 inhibits PARP and tubulin with IC₅₀s of 74 nM (PARP1), 109 nM (PARP2), and 1.4 μM (Microtubule/Tubulin), respectively. Tubulin/PARP-IN-1 can induce apoptosis and autophagy and cause cell cycle arrest in the G2/M phase ^[1].

HY-105253

PARP-2/1-IN-2	PARP	Neurological Disease
PARP-2/1-IN-2 (Compound 4a), the enantiomer of Veliparib (HY-10129), is a potent *PARP* inhibitor with K_is of 2 and 5 nM against *PARP-2* and *PARP-1, respectively. PARP-2/1-IN-2 has an EC₅₀ of 3 nM in a cell based assay of PARP activity .*

HY-15050

KCL-440

PARP Neurological Disease Inflammation/Immunology

KCL-440 is a CNS-penetrated PARP inhibitor, with an IC₅₀ of 68 nM. KCL-440 has strong inhibition of PARP-1 ^[1] .

KCL-440	PARP	Neurological Disease Inflammation/Immunology
KCL-440 is a CNS-penetrated *PARP* inhibitor, with an IC₅₀ of 68 nM. KCL-440 has strong inhibition of PARP-1 ^[1] .

HY-108632

BYK204165	PARP	Cancer
BYK204165 is a potent and selective *PARP1* inhibitor. BYK204165 inhibits cell-free recombinant human PARP-1 (hPARP-1) with a pIC₅₀ of 7.35 (pK_i=7.05), and murine PARP-2 (mPARP-2) with a pIC₅₀ of 5.38, respectively. BYK204165 displays 100-fold selectivity for PARP-1 ^[1].

HY-161288

UKTT15

PARP Cancer

UKTT15 (compound 6) is an allosteric inhibitor of PARP1 .

UKTT15	PARP	Cancer
UKTT15 (compound 6) is an allosteric inhibitor of *PARP1* .

HY-157137

PARP1-IN-17	PARP Caspase Apoptosis	Cancer
PARP1-IN-17 is a *PARP-1* inhibitor (IC₅₀ = 19.24 nM for *PARP-1* and = 32.58 nM for PARP-2) and induce apoptosis. PARP1-IN-17 shows excellent anti-proliferative activity ^[1].

HY-13688

PJ34 hydrochloride

15+ Cited Publications

PARP Cancer

PJ34 hydrochloride is an inhibitor of PARP1/2 with IC₅₀ of 110 nM and 86 nM, respectively.

PJ34 hydrochloride 15+ Cited Publications	PARP	Cancer
PJ34 hydrochloride is an inhibitor of *PARP1/2* with IC₅₀ of 110 nM and 86 nM, respectively.

HY-153590

PARP-1-IN-4	PARP	Cancer
PARP-1-IN-4 is a *PARP-1* inhibitor. PARP-1-IN-4 has inhibitory activity against PARP-1 with IC₅₀ value of 302 μM. PARP-1-IN-4 can be used for the research of lung adenocarcinoma ^[1].

HY-116218

Amelparib JPI-289	PARP	Cardiovascular Disease Neurological Disease
Amelparib is a potent, orally active, and water-soluble inhibitor of *PARP-1. Amelparib inhibits PARP-1* activity (IC₅₀ =18.5 nmol/L) and cellular PAR formation (IC₅₀ =10.7 nmol/L) in the nanomolar range. Amelparib is a potential neuroprotective agent. Amelparib has the potential for the research of acute ischaemic stroke ^[1].

HY-116218C

Amelparib hydrochloride JPI-289 hydrochloride	PARP	Cardiovascular Disease Neurological Disease
Amelparib (JPI-289) hydrochloride is a potent, orally active, and water-soluble inhibitor of *PARP-1. Amelparib hydrochloride inhibits PARP-1* activity (IC₅₀ = 18.5 nM) and cellular PAR formation (IC₅₀ = 10.7 nM). Amelparib hydrochloride is a potential neuroprotective agent. Amelparib hydrochloride has the potential for the research of acute ischaemic stroke ^[1].

HY-10162S

Olaparib-d5

AZD2281-d₅; KU0059436-d₅
PARP Autophagy Mitophagy Cancer

Olaparib-d₅ is a deuterium labeled Olaparib. Olaparib is a potent and oral PARP inhibitor[1].
HY-18954

NMS-P118

2 Publications Verification

PARP Cancer

NMS-P118 is a potent, orally available, and highly selective PARP-1 Inhibitor for cancer therapy.
HY-U00223

WD2000-012547

PARP Cancer

WD2000-012547 is a selective poly(ADP-ribose)-polymerase (PARP-1) inhibitor with a pK_i of 8.221.
HY-14478

UPF 1069

1 Publications Verification

PARP Cancer

UPF 1069 is a PARP inhibitor, with IC₅₀s of 8 and 0.3 μM for PARP-1 and PARP-2, respectively.

Olaparib-d5 AZD2281-d₅; KU0059436-d₅	PARP Autophagy Mitophagy	Cancer
Olaparib-d₅ is a deuterium labeled Olaparib. Olaparib is a potent and oral PARP inhibitor[1].

NMS-P118 2 Publications Verification	PARP	Cancer
NMS-P118 is a potent, orally available, and highly selective *PARP-1* Inhibitor for cancer therapy.

WD2000-012547	PARP	Cancer
WD2000-012547 is a selective poly(ADP-ribose)-polymerase (PARP-1) inhibitor with a pK_i of 8.221.

UPF 1069 1 Publications Verification	PARP	Cancer
UPF 1069 is a *PARP* inhibitor, with IC₅₀s of 8 and 0.3 μM for PARP-1 and PARP-2, respectively.

HY-108413

Talazoparib tosylate Maximum Cited Publications 63 Publications Verification BMN 673ts	PARP	Cancer
Talazoparib tosylate (BMN 673ts) is a novel, potent and orally available *PARP1/2* inhibitor with an IC₅₀ of 0.57 nM for PARP1.

HY-Z0283S

Benzamide-15N Benzenecarboxamide-¹⁵N; Phenylamide-¹⁵N	Endogenous Metabolite PARP	Others
Benzamide- ¹⁵N is a ¹⁵N-labeled Benzamide. Benzamide inhibits poly(ADP-ribose) polymerase (PARP)[1][2].

HY-145328

PARP-1/2-IN-1

PARP Others

PARP-1/2-IN-1 is a potent PARP-1/2 inhibitor with IC₅₀ of 0.51 nM and 23.11 nM, respectively.

PARP-1/2-IN-1	PARP	Others
PARP-1/2-IN-1 is a potent PARP-1/2 inhibitor with IC₅₀ of 0.51 nM and 23.11 nM, respectively.

HY-149800

PARP-1-IN-3	PARP Apoptosis Caspase	Cancer
PARP-1-IN-3, a benzamide derivative, is a potent *PARP-1* inhibitor with IC₅₀ values of 0.25 nM and 2.34 nM for PARP-1 and PARP-2, respectively. PARP-1-IN-3 induces apoptosis and arrest cell cycle at G2/M phase. PARP-1-IN-3 can be used in research of cancer ^[1].

HY-145734A

AMXI-5001 hydrochloride	Microtubule/Tubulin	Cancer
AMXI-5001 hydrochloride is a potent, orally active, and dual *parp1/2* and microtubule polymerization inhibitor. MXI-5001 hydrochloride exhibits selective antitumor cytotoxicity across a wide variety of human cancer cells with much lower IC₅₀s than existing clinical PARP1/2 inhibitors. AMXI-5001 hydrochloride induces complete regression of established tumors, including exceedingly large tumors ^[1].

HY-145734

AMXI-5001	Microtubule/Tubulin	Cancer
AMXI-5001 is a potent, orally active, and dual *parp1/2* and microtubule polymerization inhibitor. MXI-5001 exhibits selective antitumor cytotoxicity across a wide variety of human cancer cells with much lower IC₅₀s than existing clinical PARP1/2 inhibitors. AMXI-5001 induces complete regression of established tumors, including exceedingly large tumors ^[1].

HY-12032

AG14361 3 Publications Verification	PARP	Cancer
AG14361 is a potent *PARP-1* inhibitor, with a K_i of < 5 nM, and in permeabilized SW620 and intact SW620 cells, the IC₅₀s are 29 nM and 14 nM, respectively.

HY-128599

NMS-P515

PARP Cancer

NMS-P515 is a potent, orally active and stereospecific PARP-1 inhibitor, with a K_d of 16 nM and an IC₅₀ of 27 nM (in Hela cells). Anti-tumor activity ^[1].
HY-119653

AZ9482

PARP Cancer

AZ9482 is a triple PARP1/2/6 inhibitor, with IC₅₀ values of 1 nM, 1 nM and 640 nM for PARP1, PARP2 and PARP6, respectively ^[1].

NMS-P515	PARP	Cancer
NMS-P515 is a potent, orally active and stereospecific *PARP-1* inhibitor, with a K_d of 16 nM and an IC₅₀ of 27 nM (in Hela cells). Anti-tumor activity ^[1].

AZ9482	PARP	Cancer
AZ9482 is a triple *PARP1/2/6* inhibitor, with IC₅₀ values of 1 nM, 1 nM and 640 nM for PARP1, PARP2 and PARP6, respectively ^[1].

HY-137450

Senaparib IMP4297; JS109	PARP	Cancer
Senaparib (IMP4297) is a highly potent, selective and orally active *PARP1/2* inhibitor. Senaparib (IMP4297) exhibits strong antitumor activity in animal models ^[1].

HY-113432

Nudifloramide 2PY	Endogenous Metabolite PARP	Metabolic Disease
Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro ^[1].

HY-34386

6(5H)-Phenanthridinone
6(5H)-Phenanthridinone is a potent *PARP-1* inhibitor and immunomodulator. 6(5H)-Phenanthridinone inhibits cell proliferation and can be used in cancer research ^[1].

HY-153581

ARTD3/PARP3-IN-1

Others Others

ARTD3/PARP3-IN-1 is an unselective inhibitor of diphtheria toxin-like ADP-ribosyltransferase 3 (ARTD3)/PARP3 .

*ARTD3/PARP3-IN-1*	Others	Others
ARTD3/PARP3-IN-1 is an unselective inhibitor of diphtheria toxin-like ADP-ribosyltransferase 3 (ARTD3)/PARP3* .*

HY-N7569

Demethoxyfumitremorgin C	Apoptosis Caspase PPAR	Cancer
Demethoxyfumitremorgin C is a secondary metabolite of the marine fungus, Aspergillus fumigatus. Demethoxyfumitremorgin C induces prostate cancer cell apoptosis. Demethoxyfumitremorgin C activates caspase-3, -8, and -9, leading to PARP/ cleavage .

HY-146336

PARP1/2/TNKS1/2-IN-1	PARP Apoptosis	Cancer
PARP1/2/TNKS1/2-IN-1 (Compound I-9) is a dual *PARP-1, PARP-2, TNKS1* and TNKS2 inhibitor with IC₅₀ values of 0.25 nM, 1.2 nM, 13.5 nM and 4.15 nM against PARP-1, PARP-2, TNKS1 and TNKS2, respectively. PARP1/2/TNKS1/2-IN-1 exhibits favorable synergistic antitumor efficacy and induces apoptosis ^[1].

HY-132297A

PARP1-IN-5 dihydrochloride 1 Publications Verification	PARP	Cancer
PARP1-IN-5 dihydrochloride is a low toxicity, orally active, potent and selective *PARP-1* inhibitor (IC₅₀ =14.7 nM). PARP1-IN-5 dihydrochloride can be used for the research of cancer ^[1].

HY-132297

PARP1-IN-5

PARP Cancer

PARP1-IN-5 is a low toxicity, orally active, potent and selective PARP-1 inhibitor (IC₅₀ =14.7 nM). PARP1-IN-5 can be used for the research of cancer ^[1].

PARP1-IN-5	PARP	Cancer
PARP1-IN-5 is a low toxicity, orally active, potent and selective *PARP-1* inhibitor (IC₅₀ =14.7 nM). PARP1-IN-5 can be used for the research of cancer ^[1].

HY-162363

MD6a	PARP	Neurological Disease
MD6a is a melatonin derivative with inhibitroy activity towards *PARP-1, which maintains proteins hemostasis and improves mitochondrial function through TOR*/HSF-1 signaling. MD6a a neuroprotective effect ^[1].

HY-130644

iRucaparib-AP6 1 Publications Verification	PROTACs PARP	Cancer
iRucaparib-AP6 is a highly efficient and specific PROTAC PARP1 degrader. iRucaparib-AP6, a non-trapping PARP1 degrader, blocks both the catalytic activity and scaffolding effects of PARP1 ^[1].

HY-122661

Mefuparib hydrochloride MPH	PARP Apoptosis	Cancer
Mefuparib hydrochloride (MPH) is an orally active, substrate-competitive and selective *PARP1/2* inhibitor with IC₅₀s of 3.2 nM and 1.9 nM, respectively. Mefuparib hydrochloride induces apoptosis and possesses prominent anticancer activity in vitro and in vivo ^[1] .

HY-105303

CEP-9722	PARP	Cancer
CEP-9722, the proagent of CEP-8983, is a selective and orally active *PARP-1* and *PARP-2* inhibitor with IC₅₀s of 20 nM and 6 nM, respectively. CEP-9722 has anticancer effects ^[1] .

HY-16106

Talazoparib Maximum Cited Publications 63 Publications Verification BMN-673; LT-673	PARP	Cancer
Talazoparib (BMN-673) is a highly potent, orally active *PARP1/2* inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with K_is of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity ^[1].

HY-134354

pNP-ADPr ADP-ribose-pNP	Poly(ADP-ribose) Glycohydrolase (PARG)	Others
pNP-ADPr is a colorimetric substrate that used for the first continuous Poly(ADP-ribose) glycohydrolase (PARG) and ADP-ribosyl hydrolase 3 (ARH3) activity assays. pNP-ADPr can be used for the research of poly(ADP-ribose)polymerase (PARP) enzymes .

HY-N1094

Verminoside	PARP MDM-2/p53	Inflammation/Immunology
Verminoside is an iridoid isolated from Kigelia africana, exhibits anti-inflammatory and remarkable antioxidant activity with a radical-scavenging activity of 2.5 μg/mL. The genotoxicity of Verminoside on human lymphocytes is associated with elevated levels of *PARP-1* and p53 proteins ^[1] .

HY-149348

DiPT-4	Topoisomerase PARP Apoptosis	Cancer
DiPT-4 is a dual *TOP1/PARP1* inhibitor that induces massive DNA double-strand breaks (DSBs), cell cycle arrest, and apoptosis in cancer cells. DiPT-4 has the potential to overcome cancer drug resistance ^[1].

HY-134354A

pNP-ADPr disodium ADP-ribose-pNP disodium	Poly(ADP-ribose) Glycohydrolase (PARG)	Others
pNP-ADPr disodium is a colorimetric substrate that used for the first continuous Poly(ADP-ribose) glycohydrolase (PARG) and ADP-ribosyl hydrolase 3 (ARH3) activity assays. pNP-ADPr disodium can be used for the research of poly(ADP-ribose)polymerase (PARP) enzymes .

HY-114869

DPQ	PARP	Neurological Disease
DPQ is a potent *PARP-1* inhibitor. DPQ can reduce the N-methyl-d-aspartate (NMDA)-induced PARP activation, restoring ATP to near control levels and significantly attenuating neuronal injury in the severe NMDA exposure model. DPQ can be used for researching neuroprotection ^[1].

HY-14688

CEP-8983	PARP	Cancer
CEP-8983 is a *PARP-1* and *PARP-2* inhibitor (IC₅₀: 20 and 6 nM). CEP-8983 is an effective chemosensitizing agent, and can sensitize chemotherapy-resistant cell lines and subcutaneous xenografts to Temozolomide (HY-17364) and Camptothecin (HY-16560) ^[1].

HY-144642

PARP-1-IN-1	PARP	Cancer
PARP-1-IN-1 is a high selective and orally active *PARP-1* inhibitor (IC₅₀=0.96 nM). PARP-1-IN-1 has well tolerance and remarkable single dose activity in the MDA-MB-436 xenotransplantation model ^[1].

HY-113432S

Nudifloramide-d3	Endogenous Metabolite PARP	Metabolic Disease
Nudifloramide-d₃ (2PY-d3) is the deuterium labeled Nudifloramide. Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro[1].

HY-105692

DR2313	PARP	Neurological Disease
DR2313 is a potent, selective, competitive and brain-penetrant inhibitor of poly(ADP-ribose) polymerase (PARP), with IC₅₀s of 0.20 μM and 0.24 μM for *PARP-1* and *PARP-2*, respectively. DR2313 exhibits neuroprotective effects on ischemic injuries in vitro and in vivo ^[1] .

HY-156419

PARP7-IN-16	PARP	Cancer
PARP7-IN-16 (compound 36) is a potent, selective and orally active inhibitor of *PARP-1/2/7, with IC₅₀s of 0.94, 0.87 and 0.21 nM, respectively. PARP*7-IN-16 can be used for the research of breast cancer and prostate cancer ^[1].

HY-157212

PARP-1/Proteasome-IN-1	Apoptosis PARP Proteasome	Cancer
PARP-1/Proteasome-IN-1 (compound 42i) is a dual PARP-1 and proteasome inhibitor with significant inhibitory effects on breast cancer. *PARP-1/Proteasome*-IN-1 can downregulate the expression of BRCA1 and RAD51 to inhibit homologous recombination repair function and induce apoptosis ^[1].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113432

Nudifloramide 2PY	Alkaloids Structural Classification Classification of Application Fields Other disease Source classification Disease markers Pyridine Alkaloids Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite PARP
Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro ^[1].

HY-N1094

Verminoside	other families Iridoids Classification of Application Fields Anti-aging Terpenoids Source classification Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields	PARP MDM-2/p53
Verminoside is an iridoid isolated from Kigelia africana, exhibits anti-inflammatory and remarkable antioxidant activity with a radical-scavenging activity of 2.5 μg/mL. The genotoxicity of Verminoside on human lymphocytes is associated with elevated levels of *PARP-1* and p53 proteins ^[1] .

HY-N3584

Paris saponin VII 1 Publications Verification Chonglou SaponIN VII	Liliaceae Classification of Application Fields Source classification Trillium tschonoskii Maxim. Plants Disease Research Fields Steroids Cancer	Akt p38 MAPK P-glycoprotein Bcl-2 Family Caspase PARP Autophagy Apoptosis
Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii. Paris saponin VII-induced apoptosis in K562/ADR cells is associated with Akt/MAPK and the inhibition of P-gp. Paris saponin VII attenuates mitochondrial membrane potential, increases the expression of apoptosis-related proteins, such as Bax and cytochrome c, and decreases the protein expression levels of *Bcl-2, caspase-9, caspase-3, PARP-1, and p-Akt*. Paris saponin VII induces a robust autophagy in K562/ADR cells and provides a biochemical basis in the treatment of leukemia ^[1].

HY-N7569

Demethoxyfumitremorgin C	Structural Classification Alkaloids Microorganisms Source classification Marine natural products Other marine organisms Indole Alkaloids	Apoptosis Caspase PPAR
Demethoxyfumitremorgin C is a secondary metabolite of the marine fungus, Aspergillus fumigatus. Demethoxyfumitremorgin C induces prostate cancer cell apoptosis. Demethoxyfumitremorgin C activates caspase-3, -8, and -9, leading to PARP/ cleavage .

Cat. No.	Product Name	Chemical Structure

HY-10162S

Olaparib-d5

Olaparib-d₅ is a deuterium labeled Olaparib. Olaparib is a potent and oral PARP inhibitor[1].
HY-Z0283S

Benzamide-15N

Benzamide- ¹⁵N is a ¹⁵N-labeled Benzamide. Benzamide inhibits poly(ADP-ribose) polymerase (PARP)[1][2].

HY-113432S

Nudifloramide-d3
Nudifloramide-d₃ (2PY-d3) is the deuterium labeled Nudifloramide. Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

PARP-IN-1

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products